Cancer cells reprogramme one‐carbon metabolism (OCM) to sustain growth and proliferation. Depending on cell demands, serine hydroxymethyltransferase (SHMT) dynamically changes the fluxes of OCM by reversibly converting serine and tetrahydrofolate (THF) into 5,10‐methylene‐THF and glycine. SHMT is a tetrameric enzyme that mainly exists in three isoforms; two localize in the cytosol (SHMT1/SHMT2α) and one (SHMT2) in the mitochondria. Both the cytosolic isoforms can also translocate to the nucleus to sustain de novo thymidylate synthesis and support cell proliferation. Finally, the expression levels of the different isoforms are regulated to a certain extent by a yet unknown crosstalk mechanism. We have designed and fully characterized a set of three SHMT1 mutants, which uncouple the oligomeric state of the enzyme from its catalytic activity. We have then investigated the effects of the mutations on SHMT1 nuclear localization, cell viability and crosstalk in lung cancer cells (A549; H1299). Our data reveal that in these cell lines de novo thymidylate synthesis requires SHMT1 to be active, regardless of its oligomeric state. We have also confirmed that the crosstalk between the cytosolic and mitochondrial SHMT actually takes place and regulates the expression of the two isoforms. Apparently, the crosstalk mechanism is independent from the oligomeric state and the catalytic activity of SHMT1.Database: Structural data are available in the PDB under the accession number 6FL5
The widespread expression of many therapeutic targets in both diseased and healthy tissues presents a significant challenge for protein therapeutics, often resulting in dose-limiting side effects. To focus the action of biotherapeutics at the disease site, they can be reversibly inactivated by tethering an affinity mask through a linker cleavable by a disease-specific cue. However, current methods to generate affinity masks require extensive screening of masking sequence libraries. Here, we report a workflow to design the first de novo peptide masks for the reversible inactivation of miniprotein binders and we show its application on an EGFR antagonist miniprotein. By extending the C-terminus of the miniprotein to cover the binding interface, a masking sequence is generated that decreases binding to EGFR over 1000 times. Binding of the parental miniprotein can be fully rescued by cleavage of the linker between the binder and the mask with tumor-specific proteases. Additionally, by site-specifically conjugating the peptide mask through a chemical linker, we show we can render the protein responsive to alternative stimuli such as light. Our approach opens the doors to dramatically accelerating the development of affinity-based masks for other proteins with therapeutic potential to render them conditionally active to any stimulus.